Matthew and Ron dive into the debate on whether Medicare should cover every FDA-approved drug, focusing on the case of Aduhelm and Leqembi, two Alzheimer's drugs. Aduhelm was is not covered by Medicare due to limited effectiveness and high cost. The Centers for Medicare and Medicaid Services announced Leqemebi would be in certain circumstances.